



## **First day of trading in TO 1 in Scandion Oncology**

**In June/July 2019, Scandion Oncology A/S ("Scandion Oncology") conducted a rights issue of units in which the general public was given the opportunity to subscribe. Through the rights issue, a total of 7,144,590 shares and 2,381,530 warrants of series TO 1 were issued. First day of trading in TO 1, ISIN DK0061144078, will be on Thursday, 8 August 2019.**

### **Financial adviser, issuing agent and legal adviser**

Sedermøra Fondkommission is the financial advisor and issuing agent to Scandion Oncology in connection with the rights issue. Markets & Corporate Law acts as the legal advisor.

### **For more information regarding Scandion, please contact:**

Nils Brüner, CEO

Phone: +45 26 14 47 08

E-mail: [nb@scandiononcology.com](mailto:nb@scandiononcology.com)

[www.scandiononcology.com](http://www.scandiononcology.com)

**Scandion Oncology A/S** is a biotechnology company founded in 2017 for the purpose of addressing and tackling one of the greatest challenges in modern oncology – the effective treatment of cancer which contains drug resistant cell clones or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical animal studies, the company's leading candidate drug, SCO-101, was found to significantly enhance the efficacy of certain standard cancer treatments when given in combination. In addition, SCO-101 restores chemotherapy sensitivity in in vitro grown resistant cancer cells. Scandion Oncology will in Q4 2019 initiate a clinical phase II study with SCO-101 in combination with chemotherapy. Scandion Oncology was listed on Spotlight, Sweden in November 2018.